Sagimet Biosciences Inc. Operating Lease Cost
Sagimet Biosciences Inc. (SGMT) reported Operating Lease Cost of $40.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-11
- Sagimet Biosciences Inc. operating lease, cost for the quarter ending 2026-06-30 was $40.00K, a 2.44% decline year-over-year.
- Sagimet Biosciences Inc. operating lease, cost for the quarter ending 2026-03-31 was $40.00K, a 2.56% increase year-over-year.
- Sagimet Biosciences Inc. operating lease, cost for the quarter ending 2025-12-31 was -$118.80M.
- Sagimet Biosciences Inc. operating lease, cost for the quarter ending 2025-09-30 was $39.00M, a 7.14% decline year-over-year.
- Sagimet Biosciences Inc. operating lease, cost for fiscal 2025 was $200.00K, a 0.00% change from fiscal 2024.
- Sagimet Biosciences Inc. operating lease, cost for fiscal 2024 was $200.00K, a 0.00% change from fiscal 2023.
- Sagimet Biosciences Inc. operating lease, cost for fiscal 2023 was $200.00K, a 0.00% change from fiscal 2022.
- Sagimet Biosciences Inc. operating lease, cost for fiscal 2022 was $200.00K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 6 month as first filed | Operating Lease, Cost 9 month | Operating Lease, Cost 9 month as first filed | Operating Lease, Cost 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $40.00K 10-Q · filed 2026-08-11 | $80.00K 10-Q · filed 2026-08-11 | -$118.72M derived: sum of 3 quarters · filed 2026-08-11 | -$79.72M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | $40.00K 10-Q · filed 2026-05-12 | -$118.76M derived: sum of 2 quarters · filed 2026-05-12 | -$79.76M derived: sum of 3 quarters · filed 2026-05-12 | -$79.72M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | -$118.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$79.80M derived: sum of 2 quarters · filed 2026-03-11 | -$79.76M derived: sum of 3 quarters · filed 2026-08-11 | $200.00K 10-K · filed 2026-03-11 | |||
| 2025-09-30 | $39.00M 10-Q · filed 2025-11-13 | $39.04M derived: sum of 2 quarters · filed 2026-08-11 | $119.00M 10-Q · filed 2025-11-13 | -$76.72M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | $41.00K 10-Q · filed 2026-08-11 | $41.00M 10-Q · filed 2025-08-13 | $80.00K 10-Q · filed 2026-08-11 | $80.00M 10-Q · filed 2025-08-13 | -$115.72M derived: sum of 3 quarters · filed 2026-08-11 | -$73.72M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $39.00K 10-Q · filed 2026-05-12 | -$115.76M derived: sum of 2 quarters · filed 2026-05-12 | -$73.76M derived: sum of 3 quarters · filed 2026-05-12 | -$73.72M derived: sum of 4 quarters · filed 2026-05-12 | |||
| 2024-12-31 | -$115.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$73.80M derived: sum of 2 quarters · filed 2026-03-11 | -$73.76M derived: sum of 3 quarters · filed 2026-03-11 | $200.00K 10-K · filed 2026-03-11 | |||
| 2024-09-30 | $42.00M 10-Q · filed 2025-11-13 | $42.00K 10-Q · filed 2024-11-14 | $42.04M derived: sum of 2 quarters · filed 2025-11-13 | $116.00M 10-Q · filed 2025-11-13 | $116.00K 10-Q · filed 2024-11-14 | $42.16M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $37.00K 10-Q · filed 2025-08-13 | $74.00M 10-Q · filed 2025-08-13 | $74.00K 10-Q · filed 2024-08-14 | $163.00K derived: sum of 3 quarters · filed 2025-08-13 | $200.00K derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $37.00K 10-Q · filed 2025-05-08 | $126.00K derived: sum of 2 quarters · filed 2025-05-08 | $163.00K derived: sum of 3 quarters · filed 2025-05-08 | $200.00K derived: sum of 4 quarters · filed 2025-05-08 | |||
| 2023-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $126.00K derived: sum of 2 quarters · filed 2025-03-12 | $163.00K derived: sum of 3 quarters · filed 2025-03-12 | $200.00K 10-K · filed 2025-03-12 | |||
| 2023-09-30 | $37.00K 10-Q · filed 2024-11-14 | $74.00K derived: sum of 2 quarters · filed 2024-11-14 | $111.00K 10-Q · filed 2024-11-14 | $198.00K derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $37.00K 10-Q · filed 2024-08-14 | $74.00K 10-Q · filed 2024-08-14 | $161.00K derived: sum of 3 quarters · filed 2024-08-14 | $199.00K derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | $37.00K 10-Q · filed 2024-05-15 | $124.00K derived: sum of 2 quarters · filed 2024-05-15 | $162.00K derived: sum of 3 quarters · filed 2024-05-15 | $200.00K derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $125.00K derived: sum of 2 quarters · filed 2024-03-25 | $163.00K derived: sum of 3 quarters · filed 2024-03-25 | $200.00K 10-K · filed 2024-03-25 | |||
| 2022-09-30 | $38.00K 10-Q · filed 2023-11-13 | $76.00K derived: sum of 2 quarters · filed 2023-11-13 | $113.00K 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | $38.00K 10-Q · filed 2023-08-21 | $75.00K 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |